mcc-950 has been researched along with Coronavirus-Infections* in 1 studies
1 other study(ies) available for mcc-950 and Coronavirus-Infections
Article | Year |
---|---|
Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.
NLRP3 inflammasome mediated release of interleukin-1β (IL-1β) has been implicated in various diseases, including COVID-19. In this study, rationally designed alkenyl sulfonylurea derivatives were identified as novel, potent and orally bioavailable NLRP3 inhibitors. Compound 7 was found to be potent (IL-1β IC Topics: Administration, Oral; Animals; Betacoronavirus; Cell Line, Tumor; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Dogs; Drug Stability; Humans; Inflammasomes; Interleukin-1beta; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; NLR Family, Pyrin Domain-Containing 3 Protein; Pandemics; Pneumonia, Viral; Rats; SARS-CoV-2; Structure-Activity Relationship; Sulfonylurea Compounds | 2020 |